Pfizer says the final analysis of their trial of Pfizer’s coronavirus vaccine shows it was 95% effective in preventing infections with no serious safety concerns.
Out of 170, 162 people got placebo, or plain saline shots, while eight cases got the actual vaccine.
Pfizer and its German partner BioNTech said in a joint statement,
“Efficacy was consistent across age, race and ethnicity demographics. The observed efficacy in adults over 65 years of age was over 94%.”
There were 10 severe cases of Covid-19 observed in the trial, with nine of the cases occurring in the placebo group and one in the BNT162b2 vaccinated group.”
BNT162b2 is the experimental name for the vaccine. An independent group has been keeping an eye on results,
“To date, the Data Monitoring Committee for the study has not reported any serious safety concerns related to the vaccine.
“The only Grade 3 (severe) solicited adverse event greater than or equal to 2% in frequency after the first or second dose was fatigue at 3.7% following dose 2,”
Pfizer said it will seek US Food and Drug Administration emergency use authorization “within days.”
“Based on current projections, the companies expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021.”
Moderna’s vaccine was announced this week with nearly 95% efficacy as well. This is two doses of good news!